Independent Bank Reports Record Q3 Earnings Amid Rising Non-Performing Loans

Independent Bank has announced its Q3 2026 results, highlighting record quarterly earnings of $89.7 million and a diluted earnings per share (EPS) of $1.90. Following the announcement, the stock increased by 3.6%. While traders reacted positively to the profit figures, concerns about a rise in non-performing loans, which have reached $125.7 million, have emerged. This situation raises questions for investors regarding whether the stock's performance reflects genuine confidence in the bank's earnings potential or if it represents a short-term momentum chase amid potential credit issues.

In detail, the Q3 2026 earnings summary compared to Q3 2025 shows total revenue increasing from $205.2 million to $255.4 million, marking an approximate 24% rise. Net income, excluding extra items, surged from $34.3 million to $89.7 million, representing a significant increase of about 162%. Basic EPS grew from $0.69 to $1.90, reflecting an increase of around 177%. The net interest margin also improved, rising from 3.62% to 3.89%.

Supporters of Independent Bank point to a shift in its lending strategy towards relationship-based commercial and industrial (C&I) loans, coupled with a focus on fee income and scalable technology. The bank reported a 10% annualized expansion in C&I loans in Q2 2026, transitioning away from transactional commercial real estate. The latest data indicates continued C&I growth, approximately 5% annualized, with moderate increases in commercial real estate (CRE) and construction loans. The core net interest margin was maintained at 3.76%, while reported margins reached 3.89%. Operating expenses, excluding conversion costs, showed a slight decline.

However, critics remain cautious due to ongoing risks associated with commercial real estate and conversion expenses that may undermine the earnings narrative. Concerns persist regarding the bank's high exposure to commercial real estate, particularly related to office properties. Some criticized and classified loans include a $17.4 million life science office property fully reserved and another office loan of about $14 million currently being offered for sale.